NASDAQ:APRE Aprea Therapeutics Q4 2025 Earnings Report $0.83 +0.03 (+4.33%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$0.83 +0.00 (+0.36%) As of 06/23/2026 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Aprea Therapeutics EPS ResultsActual EPS-$0.32Consensus EPS -$0.38Beat/MissBeat by +$0.06One Year Ago EPSN/AAprea Therapeutics Revenue ResultsActual Revenue$0.00 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAprea Therapeutics Announcement DetailsQuarterQ4 2025Date3/16/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsAprea Therapeutics' Q2 2026 earnings is estimated for Tuesday, August 11, 2026, based on past reporting schedules, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Aprea Therapeutics Earnings HeadlinesAprea Shareholders Approve Directors, Reverse Split FlexibilityJune 17, 2026 | tipranks.comAprea Therapeutics Shareholders Approve Reverse Stock Split Plan at Annual MeetingJune 17, 2026 | americanbankingnews.comEvery time Musk needs a company, he buys itMusk needed batteries - he built the Gigafactory. Needed solar - acquired SolarCity. Needed data - bought Twitter. The pattern is consistent: when a supplier becomes mission-critical, he acquires it. Now, with $75 billion raised in the largest IPO in history, one small power infrastructure company is the critical piece his $2 trillion empire can't run without. Dylan Jovine has the name and ticker. | Behind the Markets (Ad)Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid ...June 1, 2026 | finance.yahoo.comAprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid TumorsJune 1, 2026 | globenewswire.comAprea Therapeutics Closes Oversubscribed $30 Million Private Placement to Advance APR-1051 Development and Reports Positive Early Data from Phase 1 TrialMay 13, 2026 | quiverquant.comQSee More Aprea Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aprea Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aprea Therapeutics and other key companies, straight to your email. Email Address About Aprea TherapeuticsAprea Therapeutics (NASDAQ:APRE) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations. Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS. In addition to its lead program, Aprea maintains a pipeline of early‐stage candidates and explores combination regimens intended to enhance response rates and overcome resistance mechanisms associated with TP53 dysfunction. Aprea conducts global clinical development activities, collaborating with academic centers and biopharmaceutical partners in North America and Europe. These partnerships support Aprea’s efforts to accelerate trial enrollment, broaden access to investigational therapies and facilitate regulatory interactions across multiple jurisdictions. Founded in 2013 and headquartered in San Francisco, California, Aprea is led by a management team with extensive experience in oncology drug development. The company’s scientific leadership combines expertise in molecular biology, translational research and clinical operations to advance its precision oncology approach for patients with high‐unmet‐need cancers.View Aprea Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Micron’s Sudden Plunge May Be an AI Buying ChanceLiquid Gold: The AI Cooling Retrofit TradeCopa Holdings May Be the Airline Stock Built to Break OutBuy CrowdStrike Before the Stock Split? Here's the CaseUSA Today's Digital Revival Is Gaining Steam, But With Plenty of RiskBurlington Is Winning Over Shoppers But Investors Need PatienceInvestors Are Buying Into Sweetgreen Again—Should They? Upcoming Earnings Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
